Abstract
Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclin-dependent kinases. The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types. We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line. In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21wafl/cipl, increased binding of p21wafl/cipl with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone H1 and induced the activation of a p21 promoter reporter construct. By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between −1185 and −1482, relative to the transcription start site. Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21wafl/cipl. As a consequence, there is an increased chance of acquisition of mutations which can enhance the genesis of hepatomas. Our results also emphasize the chemotherapeutic potential of p21wafl/cipl inhibitors, particularly in the HBV-X infected hepatoma which lacks functional p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ben-David Y, Giddens EB, Letwin K and Bernstein A. . 1991 Genes Dev. 5: 908–918.
Benn J and Schneider RJ. . 1995 Proc. Natl. Acad. Sci. USA 92: 11215–11219.
Biggs JR, Kudlow JE and Kraft AS. . 1996 J. Biol. Chem. 271: 901–906.
Chisari FV. . 1996 Curr. Top. Microbiol. Immunol. 206: 149–173.
Chin YE, Kitagawa M, Su WCS, You ZH, Iwamoto Y and Fu XY. . 1996 Science 272: 719–722.
Chomzinski P and Sacchi N. . 1987 Anal. Biochem. 162: 156–159.
Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang XF. . 1995a Proc. Natl. Acad. Sci. USA 92: 5545–5549.
Datto MB, Yu Y and Wang X-F. . 1995b J. Biol. Chem. 270: 28623–28628.
Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lee E, Harper JW, Elledge SJ and Reed SI. . 1994 Cell 76: 1013–1023.
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B. . 1994 Cancer Res. 54: 1169–1174.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.
Elmore LW, Hancock AR, Chang S-F, Wang XW, Chang S, Callahan CP, Geller DA, Will H and Harris CC. . 1997 Proc. Natl. Acad. Sci. USA 94: 14707–14712.
Erhart JA and Pittman RN. . 1998 J. Biol. Chem. 273: 23533–23537.
Graham FL and Van der Eb AJ. . 1973 Virology 52: 456–457.
Grana X and Reddy P. . 1995 Oncogene 11: 211–219.
Gottlob K, Fuko M, Levrero M and Graessman A. . 1998 J. Biol. Chem. 273: 33347–33353.
Gorman CM, Moffat LF and Howard BH. . 1982 Mol. Cell. Biol. 2: 1044–1051.
Gorospe M and Holbrook NJ. . 1996 Cancer Res. 56: 457–479.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH. . 1994 Science 264: 436–440.
Kim CM, Koike K, Saito I, Miyamura T and Jay G. . 1991 Nature 351: 317–320.
Kim YH, Kang SK and Lee YI. . 1993 Biochem. Biophys. Res. Commun. 197: 894–903.
Kim YS and Kang HS. . 1984 Korean Biochem. J. 17: 7076–7081.
Kobayashi T, Consoli U, Andreeff M, Shiku H and Zhang W. . 1995 Oncogene 11: 2311–2316.
Ko JH, Miyoshi E, Noda K, Ekuni A, Kang R, Ikeda Y and Taniguchi N. . 1999 J. Biol. Chem. 274: 22941–22948.
Lautenberger JA, Burdett LA, Gunnel MA, Qi S, Watson DK, O'Brien SJ and Papas TS. . 1992 Oncogene 7: 1713–1719.
Lee YI, Bong YS, Poo HR, Lee YI, Park JG, Oh SO, Sohn MJ, Lee S, Park US, Kim NS and Hyun SW. . 1998a Gene 207: 111–118.
Lee YI, Lee S, Lee YI, Bong YS, Hyun SW, Yoo YD, Kim SJ, Kim YW and Poo HR. . 1998b Ocogene 16: 2367–2380.
Lowe SW, Ruley HE, Jacks T and Housman DE. . 1993 Cell 74: 957–967.
Maguire HF, Hoeffier JP and Siddiqui A. . 1991 Science 252: 842–844.
Moreau-Gachelin F, Ray D, Mattei MG, Tambourin P and Tavitian A. . 1989 Oncogene 4: 1449–1456.
Morgan DO. . 1995 Nature 374: 131–134.
Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H and Sakai T. . 1997 J. Biol. Chem. 272: 22199–22206.
Pardee AB. . 1989 Science 246: 603–608.
Seth A, Ascione R, Fisher RJ, Mavrothalassitis GJ, Bhat NK and Papas TS. . 1992 Cell Growth Differ. 3: 327–334.
Seth A and Papas TS. . 1990 Oncogene 5: 1761–1768.
Seth A, Watson DK, Blair DG and Papas TS. . 1989 Proc. Natl. Acad. Sci. USA 86: 7833–7837.
Shaw P, Bovey R, Tardy S, Sahil R, Sordat B and Costa J. . 1992 Proc. Natl. Acad. Sci. USA 89: 4495–4499.
Slagle BL, Lee TH, Medina D, Finegold MJ and Butel JS. . 1996 Mol. Carcinogen. 15: 261–269.
Su F and Schneider RJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 8744–8749.
Takada S, Kaneniwa N, Tsuchida N and Koike K. . 1997 Oncogene 15: 1895–1901.
Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P and Buendia MA. . 1997 Oncogene 14: 395–404.
Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P and Buendia MA. . 1998 Oncogene 17: 2115–2123.
Waldman T, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5187–5190.
Wang XW, Forrester K, Yeh H, Feitelson M, Gu JR and Harris CC. . 1994 Proc. Natl. Acad. Sci. USA. 91: 2230–2234.
Werness BA, Levine AJ and Howley PM. . 1990 Science 248: 76–79.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. . 1993 Nature 366: 701–704.
Yang BS, Hauser CA, Henked G, Colman MS, Beveren CV, Stacey KJ, Hume DA, Maki RA and Ostrowski MC. . 1996 Mol. Cell. Biol. 16: 538–547.
Yonish-Rouach E, Resnitzky D, Lotern J, Sachs L, Kimchi A and Oren M. . 1991 Nature 352: 345–347.
Zeng YX and El-Deiry SW. . 1996 Oncogene 12: 1557–1564.
Zeng YX, Somasundaram K and El-Deiry SW. . 1997 Nat. Genet. 15: 78–82.
Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB and Mercer WE. . 1995a Cancer Res. 55: 668–674.
Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D and Deisseroth AB. . 1995b Clin. Cancer Res. 1: 1051–1057.
Acknowledgements
This work was supported by grants from the Korea Ministry of Science and Technology (KS1240, KG1182).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Park, U., Park, S., Lee, Y. et al. Hepatitis B virus-X protein upregulates the expression of p21wafl/cipl and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells. Oncogene 19, 3384–3394 (2000). https://doi.org/10.1038/sj.onc.1203674
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203674
Keywords
This article is cited by
-
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Infectious Agents and Cancer (2020)
-
EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma
Scientific Reports (2016)
-
Experimental models of hepatitis B and C — new insights and progress
Nature Reviews Gastroenterology & Hepatology (2016)
-
Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53
Digestive Diseases and Sciences (2015)
-
Hepatitis B virus X gene and hepatocarcinogenesis
Journal of Gastroenterology (2011)